Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks.
Share this article
Corporate
Score 65
Bullish
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks
Apr 06, 2026 08:53 UTC
SLEO, NBIX
Immediate term
Related Articles
Score 35
JPMorgan reiterates Tesla stock rating on weak deliveries
Apr 06, 10:44
Score 25
Biogen expects $34 million charge for research and development expenses
Apr 06, 10:43
Score 35
Playtika forms committee to review strategic alternatives
Apr 06, 10:41
Score 35
Form 8K Biogen Inc For: 6 April
Apr 06, 10:41
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.